A-LIST Pulse of the Community Vol 14, December 2022

The mission of the A-LIST is to use survey results to make life better for the broader Alzheimer’s and dementia community. UsAgainstAlzheimer’s makes sure policymakers, researchers, healthcare providers, drug developers, insurers and others who serve this community understand and consider A-LIST member insights about the Alzheimer’s and dementia journey when making decisions that affect those living with the disease and caregivers. Read the full newsletter here.

Letter from Leading Alz Researchers: Journal “overstates and distorts” influence of flawed 2016 study

In a letter to the editor published in Science responding to the journal’s recent article on the apparent manipulation of data in a 2006 study of amyloid-β, two respected Alzheimer’s researchers state that the piece “overstates and distorts the effect of this paper on the Alzheimer’s field” and “does not threaten the ‘reigning theory’ of Alzheimer’s pathobiology, known as the ‘amyloid hypothesis’. The authors—Drs. Dennis Selkoe, The Vincent and Stella Coates Professor of Neurologic Diseases Harvard Medical School and Jeffrey Cummings, Director of the Chambers-Grundy Center for Transformative Neuroscience at UNLV—explain how the data in question is not a factor

A-LIST Pulse of the Community Vol 12, August 2022

The mission of the A-LIST is to leverage data to make life better for the Alzheimer’s and dementia community. UsAgainstAlzheimer’s shares our findings with policymakers, researchers, health care providers, public health officials, drug developers, insurers and others who serve this community to ensure they consider these insights when making decisions affecting people living with the disease and their caregivers. Read the full newsletter here.

A-LIST Pulse of the Community Vol 11, May 2022

The mission of the A-LIST is to use survey results to make life better for the broader Alzheimer’s andbdementia community.

Summary of Findings: UsAgainstAlzheimer’s A-LIST Survey on Medicare (CMS) Coverage Decision

Summary of Findings: UsAgainstAlzheimer’s A-LIST Survey on Medicare (CMS) Coverage Decision February 7, 2022 UsAgainstAlzheimer’s fielded a survey, January 27-February 2, 2022, with responses from 752 people who were diagnosed with Mild Cognitive Impairment (MCI)/Alzheimer’s disease (AD) or another dementia, ‘at risk’ for diagnosis, current/former caregivers and those interested in brain health Key overall findings include: 2/3 of respondents were unaware (43%) or unsure (20%) of the CMS decision Of the group that was aware of the CMS decision, few respondents were able to articulate a full awareness of the implications in an open-ended response; many of those respondents were